Results of SkQ1 U.S. Phase 2 Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal

Jan 10, 2016

Mitotech published the results of SkQ1 Ophthalmic Solution Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model in Patients with Dry Eye Syndrome in Advances in Therapy journal. This open access publication can be found here:

http://link.springer.com/article/10.1007/s12325-015-0274-5/fulltext.html

About Mitotech S.A

Mitotech S.A. is a Luxembourg-based biotechnology company developing novel drugs for the treatment of age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria addressed antioxidants. Company’s lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.